Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) FCF Margin (2018 - 2025)

BioNexus Gene Lab's FCF Margin history spans 8 years, with the latest figure at 48.86% for Q3 2025.

  • For Q3 2025, FCF Margin rose 1965.0% year-over-year to 48.86%; the TTM value through Sep 2025 reached 29.17%, up 667.0%, while the annual FY2024 figure was 25.88%, 570.0% down from the prior year.
  • FCF Margin for Q3 2025 was 48.86% at BioNexus Gene Lab, down from 33.6% in the prior quarter.
  • Across five years, FCF Margin topped out at 26.92% in Q1 2021 and bottomed at 68.52% in Q3 2024.
  • The 5-year median for FCF Margin is 4.91% (2023), against an average of 13.12%.
  • The largest YoY upside for FCF Margin was 5876bps in 2021 against a maximum downside of -320682bps in 2021.
  • A 5-year view of FCF Margin shows it stood at 14.84% in 2021, then increased by 13bps to 16.79% in 2022, then tumbled by -305bps to 34.47% in 2023, then soared by 109bps to 2.94% in 2024, then plummeted by -1762bps to 48.86% in 2025.
  • Per Business Quant, the three most recent readings for BGLC's FCF Margin are 48.86% (Q3 2025), 33.6% (Q2 2025), and 38.98% (Q1 2025).